EMBOLD – VJRegenMed

ATA3219, ATA3271 & ATA188: T-Cell immunotherapy products in development

Simon Ng — Mon, 29 Nov 2021 11:36:56 +0000

Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the pipeline of Atara Biotherapeutics including the ATA3219, an anti-CD19 allogeneic T-cell immunotherapy targeting B-cell malignancies, as well as ATA3271, a chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin for solid tumors. He additionally discusses the latest results from the Phase I/II EMBOLD study (NCT03283826) of ATA188, a T-cell immunotherapy that targets Epstein-Barr virus (EBV) in patients with progressive multiple sclerosis. This interview took place at Meeting on the Mesa 2021.

ATA188: an allogeneic EBV-specific T cell therapy for progressive MS

admin_vjr_user — Thu, 05 Aug 2021 16:47:35 +0000

Jakob Dupont, MD, MA, Atara Biotherapeutics, San Francisco, CA, describes ATA188, an off-the-shelf, healthy donor-derived T-cell immunotherapy that targets Epstein-Barr virus (EBV) for the treatment of progressive MS. He provides an overview of the Phase I/II EMBOLD study (NCT03283826) of ATA188 in patients with progressive MS. The open-label dose-escalation period of this study (Part 1) demonstrated the safety and tolerability of ATA188, with a lack of reported infusion reactions or cytokine release syndromes. The ongoing double-blind, randomized, placebo-controlled dose-expansion period (Part 2) aims to evaluate the efficacy of ATA188 through the primary outcome measure of sustained Expanded Disability Status Scale (EDSS) improvement at 12 months post-treatment. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

ATA188 in EBV+ progressive multiple sclerosis

admin_vjr_user — Mon, 05 Jul 2021 13:47:08 +0000

Latent Epstein-Barr virus (EBV) infection in B cells is associated with an increased risk of the development of multiple sclerosis (MS), so it is believed that addressing the EBV infection in MS patients could lead to significant improvement in their symptoms. Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the ongoing Phase I/II EMBOLD trial (NCT03283826) assessing the safety and efficacy of ATA188, an allogeneic EBV T-cell product that targets EBV-infected B-cells in patients with progressive MS. It is hoped that ATA188 could become the first approved treatment that reverses disability in progressive MS. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.